All News

A study finds stronger CV protection from glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with higher BMI, with kidney benefits consistent across all groups.

Central nervous system (CNS) metastases in EGFR-mutant non–small cell lung cancer (NSCLC) remain a major challenge, with emerging therapies and evolving trial designs aiming to improve outcomes and address unmet needs.

Reducing the deferral period from 12 months to 3 months for those with high-risk behaviors did not increase the incidence of infectious diseases like HIV and hepatitis B appearing in donated blood.

Cemiplimab shows significant survival benefits over chemotherapy for advanced non–small cell lung cancer (NSCLC) with high PD-L1 expression, enhancing treatment outcomes.

Navigating treatment for multiple sclerosis and comorbid inflammatory diseases presents unique challenges, requiring careful, interdisciplinary strategies for optimal patient care.

While body mass index (BMI) accurately identified excess adiposity in nearly all children and adolescents with obesity, it failed to detect many of those without obesity who still had excess body fat.

Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.

A study reveals high drug survival rates for anti-TNF biosimilars in treating psoriasis and psoriatic arthritis, highlighting their long-term efficacy and safety.

Treatment of EGFR-mutated non–small cell lung cancer (NSCLC) is shifting toward next-generation sequencing and combination regimens that improve survival but increase toxicity, requiring individualized care.

Bispecific antibodies are emerging as a transformative class in advanced non–small cell lung cancer (NSCLC), with agents such as amivantamab and zenocutuzumab already demonstrating clinical benefit and a broad pipeline of investigational therapies showing promise in overcoming resistance.

National Comprehensive Cancer Network (NCCN), the European Society for Medical Oncology (ESMO), and the American College of Chest Physicians (CHEST) offer complementary yet distinct frameworks for lung cancer care, reflecting differences in evidence evaluation, regional adaptation, and policy integration.

Discontinuing dupilumab for atopic dermatitis (AD) may increase relapse risk, which requires ongoing management and tailored treatment strategies to manage that risk.

The treatment also showed signs of metabolic gains, with more benefit seen with the 50-mg dose than the 28-mg.

Maintaining eye health through regulating use of technology and attending annual checkups are an important aspect of children’s health as the school year approaches.

Medicaid cuts could be devastating to areas where health care deserts are prevalent, especially in children, making it vital that legislators understand the potential gap in care to help close it.

The findings add confidence to the role of ritlecitinib as a treatment option for severe alopecia areata while pointing the way toward more personalized approaches.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Research highlights a strong link between Epstein-Barr virus and multiple sclerosis (MS), suggesting new therapeutic strategies targeting the virus for MS treatment.

Methotrexate significantly lowered systolic blood pressure compared with sulfasalazine in adults with newly diagnosed rheumatoid arthritis, suggesting potential cardiovascular benefits beyond its anti-inflammatory effects.

A study finds that $100 rideshare rides for follow-up colonoscopy after fecal immunochemical test (FIT) doubled completion rates, reduced colorectal cancer (CRC) deaths, and lowered health care costs.

Patients with ovarian cancer who undergo BRCA testing face higher health care resource utilization (HCRU) and costs but are more likely to receive genomically targeted therapies and progress to later lines of treatment (LOT).

BeOne Medicines reveals promising results for sonrotoclax, a next-gen BCL2 inhibitor, in treating relapsed mantle cell lymphoma, addressing critical patient needs.

A recent study reveals that over one-third of individuals with relapsing-remitting multiple sclerosis (MS) do not fully recover from relapses, highlighting critical recovery factors.

The hearing included questioning from both sides of the aisle as Robert F. Kennedy Jr defended his decisions as secretary of HHS.

New abstracts from the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025 found that ACC017 showed promise in its use as an antiretroviral therapy.

Joseph Ladapo, MD, PhD, Florida’s surgeon general, announced the move during a news conference where he stated that he would end “every last one of them.”

Despite reduced immune responses, immunization lowers infection rates and remains central to supportive care in patients with multiple myeloma.

Jack Tsai, PhD, MSCP, emphasized that comparing the methods of different jurisdictions can aid decision-making as the new executive order is enacted.